Jeremy

Peterson

Named one of the "World's Most Influential Scientific Minds" by Thomson Reuters, Jeremy Peterson's decade-long career as a scientist at the leading edge of genomic research and bioinformatics gives him a unique perspective on the protection of intellectual property. His background in bioinformatics and genomic sequencing - in addition to the patents necessary to track and safeguard those sequences - informs his deep understanding of the complex issues faced by patent holders around the world.

Whether they are seeking royalties or injunctions against the competitors who infringe on their intellectual property, or are defendants accused of patent infringement, Jeremy represents domestic and foreign-based businesses across a wide range of sectors: pharmaceuticals and medical devices, telephony and wireless communications, web applications, hardware and software programs, computers and semiconductors, optics, and personal transporters, to name a few.

Jeremy also counsels companies across the United States, in addition to China, Japan, and Korea, through the complex regulatory regime governing branded and generic products entering the U.S. market, advising on the requirements of the U.S. Food & Drug Administration and the Hatch-Waxman Act.

Highly experienced in all stages of patent litigation, from pre-suit investigation through jury trials and claim construction, Jeremy has represented businesses before the Patent Trial and Appeal Board (PTAB), in Section 337 proceedings before the U.S. International Trade Commission (ITC), and in federal district courts across the country, including the patent litigation hotbeds of the U.S. District Courts for the Eastern District of Texas, the Eastern District of Virginia, and the Northern District of California. He is also experienced in prosecuting patent applications before the U.S. Patent and Trademark Office (USPTO) and leading national stage filings under the Patent Cooperation Treaty (PCT).

Prior to law school, Jeremy spent more than ten years in research and development on large-scale sequencing projects at The Institute for Genomic Research (TIGR), where he managed the organization's bioinformatics group. He has authored or co-authored more than 30 scientific articles in journals such as Science, Nature, and Nucleic Acids Research.